Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOX + Bevacizumab +/- Radiotherapy and Iparomlimab/Tuvonralimab for Metastatic Rectal Cancer
NCT07383285Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, open-label trial of iparomlimab + tuvonralimab in rectal cancer (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 12-month Progression-Free Survival Rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07383285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07383285.